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Interleukin-18 (IL-18) plays an important role in host defense against microbial pathogens. Many poxviruses encode homologous IL-18
binding proteins (IL-18BP) that neutralize IL-18 activity. Here, we examined whether IL-18BP neutralizes IL-18 activity by binding to the same
region of IL-18 where IL-18 receptor (IL-18R) binds. We introduced alanine substitutions to known receptor binding sites of human IL-18 and
found that only the substitution of Leu5 reduced the binding affinity of IL-18 with IL-18BP of variola virus (varvIL-18BP) by more than 4-fold.
The substitutions of Lys53 and Ser55, which were not previously known to be part of the receptor binding site but that are spatially adjacent to
Leu5, reduced the binding affinity to varvIL-18BP by approximately 100- and 7-fold, respectively. These two substitutions also reduced the
binding affinity with human IL-18R alpha subunit (hIL-18Rα) by 4- and 2-fold, respectively. Altogether, our data show that varvIL-18BP prevents
IL-18 from binding to IL-18R by interacting with three residues that are part of the binding site for hIL-18Rα.
© 2006 Elsevier Inc. All rights reserved.Keywords: Poxvirus; Variola virus; Smallpox; IL-18; IL-18BP; Biacore; Surface plasmon resonanceIntroduction
Interleukin-18 (IL-18) is a pro-inflammatory cytokine that
belongs to the IL-1 superfamily (Dinarello, 2006; Gracie et al.,
2003). Similar to IL-1β, IL-18 is synthesized as an inactive
precursor (proIL-18) and becomes active only after its cleavage
by the IL-1β-converting enzyme/caspase-1. The recently
determined human IL-18 (hIL-18) structure shows a β-trefoil
fold that is similar to that of IL-1β (Kato et al., 2003). The
receptor for IL-18 (IL-18R) is a heterodimer consisting of the
ligand-binding α subunit (IL-18Rα) and the signal-transducing
β subunit (IL-18Rβ). Mutagenesis studies of hIL-18 revealed
the presence of three receptor binding sites: two of these (site I
and II) are important for IL-18Rα binding and the third (site III)
is probably involved in IL-18Rβ binding (Kato et al., 2003).
The binding of IL-18 with IL-18R results in a ternary complex
that triggers a signal cascade involving IL-1 receptor activating
kinase (IRAK), TRAF6 and NF-κB (Kojima et al., 1998;
Robinson et al., 1997).⁎ Corresponding author. Fax: +1 210 567 6612.
E-mail address: xiangy@uthscsa.edu (Y. Xiang).
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doi:10.1016/j.virol.2006.08.019IL-18 was formerly known as the interferon-γ-inducing
factor. It acts synergistically with co-stimulants to induce
interferon-γ production from T lymphocytes and macrophages
and enhances the cytotoxicity of natural killer cells (Dinarello,
2006; Gracie et al., 2003). Hence, it is an important regulator of
both innate and acquired immune responses. However, it is also
implicated in endotoxin-induced liver damage and some
chronic inflammatory diseases (Gracie et al., 2003; Tsutsui et
al., 2000). Not surprisingly, its activity is modulated in vivo by a
negative feedback mechanism involving a natural occurring IL-
18 antagonist, the IL-18 binding protein (IL-18BP) (Novick et
al., 1999), whose expression is induced by IFN-γ (Muhl et al.,
2000; Paulukat et al., 2001). IL-18BP differs significantly in
sequence from IL-18R, but it binds to IL-18 with a sub-
nanomolar affinity and prevents IL-18 from binding to its
receptor (Aizawa et al., 1999; Novick et al., 1999).
Functional homologs of IL-18BP have also been found in
poxviruses, namely molluscum contagiosum virus, vaccinia
virus, cowpox virus, variola virus and ectromelia virus (Born et
al., 2000; Calderara et al., 2001; Esteban et al., 2004; Smith et
al., 2000; Xiang and Moss, 1999). Among them, variola virus
and molluscum contagiosum virus infect humans exclusively
212 X. Meng et al. / Virology 358 (2007) 211–220(Moss, 2001). Variola virus is the causative agent for smallpox,
a deadly disease that was eradicated after a global vaccination
campaign using the closely related vaccinia virus. It is now
considered as one of the most dangerous bioterrosim agents as
the majority of the population are not immunized and no
antiviral or generally acceptable vaccine for smallpox is
available. Molluscum contagiosum virus causes small, benign
skin lesions that are usually self-limited but become more
extensive in immunocompromised individuals (Gottlieb and
Myskowski, 1994). The poxvirus-encoded IL-18BP represents
an immune evasion mechanism for poxviruses. Viral infection
induces IL-18 release, and the administration of exogenous IL-
18 in mice protects against herpes simplex virus and vaccinia
virus infections (Fujioka et al., 1999; Pirhonen, 2001; Tanaka-
Kataoka et al., 1999). Poxviral IL-18BP suppresses IL-18-
mediated activity and contributes to the virulence of ectromelia
virus and vaccinia virus (Born et al., 2000; Reading and Smith,
2003; Symons et al., 2002).
The IL-18 binding site was identified in human and several
viral IL-18BP through site-directed mutagenesis and binding
studies (Esteban and Buller, 2004; Xiang and Moss, 2001a,
2001b). Despite a relatively low overall sequence identity
between the human and viral IL-18BP, the residues that
constitute the IL-18 binding site are mostly conserved in all
IL-18BP. In the current study, we identified in hIL-18 the main
binding site for IL-18BP of variola virus (varvIL-18BP) and
found that it is also part of the binding site II for hIL-18Rα,
suggesting that varvIL-18BP neutralizes hIL-18 activity by
competing with hIL-18Rα for a common binding site.
Results
Mutagenesis and purification of hIL-18
To determine whether variola virus IL-18BP (varvIL-18BP)
competes with hIL-18R for the same binding site in hIL-18, we
set out to test whether the residues of hIL-18 that form the hIL-
18R binding sites are also important for the binding with
varvIL-18BP. 14 hIL-18 residues were previously identified to
form the binding site I, II for hIL-18Rα and the binding site III
for hIL-18Rβ (Kato et al., 2003). They are Arg13, Asp17,
Met33, Asp35 and Asp132 (Site I), Lys4, Leu5, Lys8, Arg58,Fig. 1. Mutagenesis and purification of hIL-18. (A) Locations of the mutated
residues in hIL-18 structure (PDB# 1J0S). The backbone of hIL-18 and the side
chains of 17 residues that were subjected tomutagenesis are shown. Residues at the
known binding site I, II and III for hIL-18R are colored in red, orange and blue,
respectively. The remaining three are colored in yellow. The residues are numbered
starting from the first residue of themature hIL-18. (B) Purification of proIL-18 and
the generation of mature IL-18. The schematic diagram of the recombinant proIL-
18 protein with an N-terminal 6-His tag and an engineered Factor Xa cleavage site
is shown. The proIL-18 proteins were over-expressed in E. coli and captured with
Ni-NTA resin. Mature IL-18 proteins were released from the resin by Factor Xa
digestion. Coomassie-stained protein samples are shown with the positions of
proIL-18 and mature IL-18 indicated. (C) Further purification of mature IL-18 by
size-exclusion chromatograph. Mature IL-18 proteins that were released from the
Ni-NTA resin (starting material) were applied to sephacryl S-100HR column, and
multiple protein fractions were collected. The silver-stained protein samples are
shown.Met60 and Arg104 (Site II), and Lys79, Lys84 and Asp98 (Site
III) (Fig. 1A). In addition, Glu6, Lys53 and Ser55 were also
chosen for substitution. Glu6 and Lys53 were previously
suggested by molecular modeling to be part of the binding site
for human IL-18BP, and hIL-18 mutant with K53A substitution
is more resistant to neutralization by human IL-18BP (Kim et
al., 2000, 2001). (Glu6 and Lys53 were previously referred to as
213X. Meng et al. / Virology 358 (2007) 211–220Glu42 and Lys89 by Kim et al., who numbered the residues
from the first residue of IL-18 precursor.) Ser55 was specifically
chosen for substitution after examination of hIL-18 structure
following our preliminary studies. It is a surface residue that is
spatially adjacent to Lys53 (Fig. 1A). Altogether, 17 hIL-18
residues were individually substituted with alanine.
All the hIL-18 proteins, wild type or mutated, were
expressed in E. coli as the precursor form (proIL-18), in
which the caspase-1 cleavage site was substituted with the
Factor Xa site (Fig. 1B), similar to a previous report (Liu et al.,
2000). The proIL-18 proteins were bound to metal affinity resin
via an N-terminal 6-His tag (Fig. 1B). The authentic, mature
hIL-18 proteins were released from the resin by Factor Xa
digestion and further purified by size-exclusion chromatogra-
phy (Figs. 1B and C). A protein fraction which consisted almost
exclusively of the mature IL-18, such as fraction #2 or #3 in Fig.
1C, was used in subsequent binding studies.
Construction and expression of variola virus IL-18BP
The coding sequence for varvIL-18BP was constructed by
mutagenizing the closely related IL-18BP of ectromelia virus
(ectvIL-18BP) as variola virus genomic DNA is not readily
available. Only six residues are different between IL-18BPs of
variola virus and ectromelia virus naval strain (Fig. 2A) and the
mutagenesis of ectvIL-18BP at these six residues resulted in
varvIL-18BP. To express a recombinant varvIL-18BP protein
with a C-terminal biotinylation site and a 6-His tag for
subsequent binding analysis, the coding sequence for varvIL-
18BP was cloned into a mammalian expression vector thatFig. 2. The construction and expression of variola virus IL-18BP (varvIL-18BP).
(A) The alignment of IL-18BPs of ectromelia virus and variola virus. Six amino
acids that are different between the two proteins are indicated by their residue
numbers. These six residues were mutated in ectromelia virus IL-18BP (ectvIL-
18BP) to generate varvIL-18BP. (B) Detection of in vitro biotinylated varvIL-
18BP and ectvIL-18BP. Recombinant IL-18BPs were transiently expressed in
293T cells, bound to Ni-NTA resin and biotinylated on the resin by biotin
holoenzyme synthetase. The proteins were eluted from the resin with buffer
containing imidazole, and the biotinylated species were detected by chemilu-
minescence with a streptavidin–horseradish peroxidase conjugate after Western
blotting. The positions and masses in kDa of protein markers are shown on the
left.encodes the tags and that was previously used for the study of
human and molluscum contagiosum virus IL-18BP (Xiang and
Moss, 2001a, 2001b). The recombinant varvIL-18BP was
transiently expressed in HEK293T cells, purified from the
culture medium via the 6-His tag and biotinylated at the C-
terminal site by biotin holoenzyme synthetase. The biotinylated
varvIL-18BP reacted specifically to streptavidin in Western
blotting and migrated slightly faster than similarly biotinylated
ectvIL-18BP on SDS-PAGE gel (Fig. 2B). The reason for the
small change in gel mobility is unclear but is not due to any un-
intended mutation in coding sequence of varvIL-18BP, as it was
confirmed by sequencing.
Alanine substitution of Leu5, Lys53 and Ser55 significantly
decreased the binding affinity of hIL-18 with varvIL-18BP
Biotinylated varvIL-18BP was immobilized on a BIAcore
sensor chip coated with streptavidin, and its binding with various
mutated hIL-18 proteins was monitored in real time with a
BIAcore 3000 sensor. The sensorgram of the wild type (WT)
hIL-18 showed a quick increase in signal during the association
phase and a slow decline in signal during the dissociation phase
(Fig. 3), demonstrating a fast on rate and a slow off rate. While
the on rate was proportional to the concentration of hIL-18 that
was injected, the off rate was independent of the protein
concentration and indicative of the affinity between hIL-18 and
varvIL-18BP. The slow off rate observed with the WT hIL-18
was not altered significantly by mutations of the known IL-18R
binding sites except for the substitution of Leu5 (L5A) (Figs. 3A,
B, C), which increased the off rate significantly. The off rate was
increased even more by the substitution of Ser55 (S55A) or
Lys53 (K53A) but was not affected significantly by the
substitution of Glu6 (E6A) (Fig. 3D).
To obtain the kinetic and affinity constants, sensorgrams
were acquired with different concentrations of the same hIL-18
protein and globally fitted to a 1-to-1 binding model with
BIAEVALUATION software (Fig. 4). The WT hIL-18 bound to
varvIL-18BP with a KD of 3 nM, in agreement with a previous
report (Esteban et al., 2004). K53A, S55A and L5A substitu-
tions increased the KD 100-, 7- and 4-fold, respectively, while
no other mutation altered the KD by more than 2-fold (Table 1).
Leu5, Lys53 and Ser55 form a contiguous surface patch (Fig.
1A), suggesting that they are part of a single binding site for
varvIL-18BP.
Alanine substitution of Lys53 and Ser55 also decreased the
binding affinity of hIL-18 with hIL-18Rα
Glu6, Lys53 and Ser55 are spatially adjacent to the
binding site II for IL-18Rα (Fig. 1A), so they were also
evaluated for their contribution towards IL-18Rα binding
with BIAcore. Similar to varvIL-18BP, the ectodomain of
human IL-18Rα (amino acids 1–229) was expressed in
HEK293T cells with a C-terminal biotinylation site and 6-His
tag, purified from the culture medium, biotinylated with biotin
holoenzyme synthetase and immobilized on a streptavidin-
coated BIAcore sensor chip (Fig. 5A). The WT hIL-18 bound
Fig. 3. The binding affinity of hIL-18 with varvIL-18BP is reduced by alanine substitution of Leu5, Lys53 or Ser55. The biotinylated varvIL-18BP was captured on a
BIAcore streptavidin-coated SA chip, and its binding with hIL-18 proteins was monitored in real time with a BIAcore 3000 sensor. The colored lines are the responses
obtainedwith different hIL-18mutants. Shown in the same color are the name and protein concentration of the respectivemutant. The injection of hIL-18 started at 100 s
and stopped at 400 s.
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5B). The KD for the WT and the L5A mutant was 3 and
30 nM, respectively, in agreement with a previous report
(Kato et al., 2003). The E6A substitution did not decrease the
affinity of hIL-18 with hIL-18Rα, but K53A and S55A
substitutions decreased the affinity by more than 4- and 2-
fold, respectively (Fig. 5B), indicating that Lys53 and Ser55
are also part of the binding site for hIL-18Rα.
The finding that K53A substitution decreased the affinity of
hIL-18 with hIL-18Rα was rather unexpected as K53A
substitution was previously reported to enhance IL-18 activity
(Kim et al., 2001). Indeed, the K53A mutant induced the
secretion of a higher level of IFN-γ from human macrophagic
KG-1 cells than the WT hIL-18 (Fig. 6). In contrast, L5A
mutant induced a lower level of IFN-γ secretion than the WT
hIL-18 (Fig. 6), also in agreement with a previous report (Kato
et al., 2003). The level of secreted IFN-γ induced by the S55A
mutant was lower than that by the WT hIL-18 at high hIL-18
concentrations but was higher than that by the WT at low IL-18
concentrations (Fig. 6). These results suggest that IL-18 activity
does not necessarily correlate with the affinity between hIL-18
and IL-18Rα.
Taken altogether, the data suggest that varvIL-18BP
neutralizes hIL-18 activity by competing with hIL-18Rα for
the binding of Leu5, Lys53 and Ser55 (Fig. 7).Discussion
Variola virus is one of the most feared bioterrorism agents.
However, an understanding of variola virus pathogenesis at
the molecular level is not yet available for the development of
a therapy for smallpox as smallpox was eradicated before
modern molecular techniques became available. In the current
study, we focused on varvIL-18BP, a putative virulence factor
for variola virus. We identified Leu5, Lys53 and Ser55 of hIL-
18 to be the binding site for varvIL-18BP. In addition, we
found that Lys53 and Ser55 were also part of a binding site for
hIL-18Rα. This finding, together with the previous knowledge
that Leu5 was part of the binding site II for hIL-18Rα (Kato et
al., 2003), reveals that varvIL-18BP neutralizes hIL-18 activity
by competing with hIL-18Rα for the binding of three common
residues. Although the varvIL-18BP binding site in hIL-18 is
only a small part of the much bigger IL-18R binding site, the
binding of varvIL-18BP with IL-18 presumably will create
steric interference and prevent IL-18R from interacting with
the rest of site II residues. It is quite remarkable for varvIL-
18BP to target the same residues that hIL-18Rα binds as IL-
18BP shares no significant amino acid sequence homology
with IL-18R. This knowledge may be beneficial for the
development of reagents to block varvIL-18BP as part of a
therapy for smallpox.
Fig. 4. Kinetic analyses of the binding to varvIL-18BP by L5A, K53A and S55Amutants. BIAcore sensorgrams were obtained similarly as described in Fig. 3 but with
different concentrations of the same hIL-18 mutant. The response curves were globally fitted to a 1:1 binding model with the obtained kinetics constant shown. The
colored and black lines are the actual responses in RU and globally fitted curves, respectively. The residual responses, below each set of curves, represent deviations of
the actual responses from the fitted curves.
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neutralizes IL-18 may also help the development of small
molecule inhibitors of IL-18. IL-18 activity has been implicated
in autoimmune diseases, and human IL-18BP is currently in
clinical trials for the treatment of rheumatoid arthritis and severe
psoriasis (Dinarello, 2000; Dinarello, 2006). Our study on IL-
18's binding site for varvIL-18BP represents the first such study
for any IL-18BP. The role of Lys53 in binding with human IL-
18BP was previously suggested by molecular modeling and by
hIL-18BP neutralization assay (Kim et al., 2000, 2001), but the
direct evidence for such a role was not available. Leu5 and
Ser55 were identified in this study by analyzing 17 mutations of
hIL-18 surface residues, the majority of which did not affect the
affinity with varvIL-18BP. Interestingly, Leu5, Lys53 and Ser55
form a contiguous surface patch (Fig. 7A), consistent with their
being a single binding site for IL-18BP. These residues are
conserved among mammalian IL-18 proteins and possibly serve
as a binding site for other viral and mammalian IL-18BPs,
which bind to hIL-18 via a conserved set of residues (Fig. 7B)
(Xiang and Moss, 2001a, 2001b).
The finding that K53A substitution reduces the affinity of
hIL-18 with varvIL-18BP by 100-fold indicates that Lys53 is a
binding free energy “hot spot”. Previously, three aromaticresidues of human IL-18BP were identified to be the hot spot for
the interaction with hIL-18 (Fig. 7B) as these three residues
contribute 68% of the total binding free energy of hIL-18 and
human IL-18BP (Xiang and Moss, 2001b). Subsequently, the
corresponding residues in molluscum contagiosum virus and
ectromelia virus IL-18BPs were also found to be critical for the
interaction with both human and mouse IL-18 (Esteban and
Buller, 2004; Xiang and Moss, 2001a). Amino acids with
aromatic side chains are often found at the interface of protein
complex to form high energy π-cation pair with side chains
bearing positive charge (Crowley and Golovin, 2005; Zacharias
and Dougherty, 2002). This π-cation interaction is electrostatic
in nature and calculated to be stronger than a typical salt-bridge
(Zacharias and Dougherty, 2002). Half of the protein complexes
that were examined contain at least one π-cation pair (Crowley
and Golovin, 2005). It is possible that Lys53 of hIL-18 interacts
with the critical aromatic residues of IL-18BP to form the high
energy π-cation pair.
The finding that Lys53 and Ser55 contribute to the binding
with hIL-18Rα expands the known boundary of the binding
site II for hIL-18Rα. This finding on Lys53 was initially
surprising for us as K53A substitution was previously shown
to enhance hIL-18 activity (Kim et al., 2001), a finding that
Table 1
Kinetics and affinity constants of hIL-18 mutants with varvIL-18BP
hIL-18 mutants a Kon, 10
4/ms Koff, 10
−4/s KD, nM
WT 6.9±0.5 2.1±0.1 3.1±0.1
K4A 8.7±0.1 2.8±0.2 3.2±0.2
L5A 6.8±0.1 8.8±0.1 12.9±0.1
E6A 7.1±0.1 3.7±0.2 5.5±0.2
K8A 6.5±0.1 1.9±0.1 2.9±0.1
R13A 7.6±0.1 3.8±0.2 4.9±0.2
D17A 7.8±0.1 2.5±0.2 3.2±0.2
M33A 7.6±0.2 2.6±0.1 3.4±0.1
D35A 7.8±0.1 2.1±0.1 2.7±0.1
K53A 6.0±0.1 230±70 400±100
S55A 4.6±0.1 9.1±0.5 20±2
R58A 8.1±0.4 4.5±0.1 5.6±0.1
M60A 6.5±0.1 2.9±0.1 4.4±0.1
K79A 6.7±0.1 2.0±0.1 3.0±0.3
K84A 6.3±0.2 1.8±0.1 2.8±0.2
D98A 8.3±0.8 2.9±0.3 3.5±0.1
R104A 7.9±0.1 2.8±0.1 3.5±0.1
D132A 7±1 4.6±0.5 6±2
a The kinetics and affinity constants were derived from 2 independent
experiments similar to those shown in Fig. 4. K values are means±standard
deviations.
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enhances IL-18 activity also suggests that the substitution does
not have any deleterious effect on hIL-18 structure. K53A
reduces the affinities with varvIL-18BP and IL-18Rα by 100-
and 4-fold, respectively, so Lys53 is clearly more critical for
the binding with varvIL-18BP than with IL-18Rα. Lys53 may
similarly be more critical for the binding with human IL-18BP
than with IL-18Rα, which is consistent with the previous
report that K53A is more resistant to neutralization by human
IL-18BP (Kim et al., 2001). K53A enhances IL-18 activity
probably by greatly reducing the ability of human IL-18BP to
bind and neutralize the mutated hIL-18. Although human IL-
18BP expression has not been shown in the human
macrophagic KG-1 cells that were used in this study, its
expression was shown to be induced by IFN-γ in primary
monocytes/macrophages (Corbaz et al., 2002; Veenstra et al.,
2002) as well as in nonleukocytic cell lines such as
keratinocytes, epithelial cells and renal mesangial cells
(Muhl et al., 2000; Paulukat et al., 2001). Our results are
consistent with the idea that hIL-18 activity is regulated by its
relative affinities with hIL-18R and human IL-18BP. S55A
reduces the affinities with varvIL-18BP and IL-18Rα by 6-
and 2-fold, respectively, so Ser55 is more important for the
binding with varvIL-18BP than with hIL-18Rα. Ser55 may
similarly be more important for binding with human IL-18BP
than with hIL-18Rα, which could explain why S55A enhances
IL-18 activity at low IL-18 concentration. In contrast to Lys53
and Ser55, Leu5 is more important for the interaction with
hIL-18Rα than with varvIL-18BP as L5A decreases the
affinity with hIL-18Rα and varvIL-18BP by 10- and 4-fold,
respectively. Leu5 may similarly be more important for the
binding with hIL-18Rα than with human IL-18BP, so L5A
reduces IL-18 activity. The fact that each substitution caused
different effects on IL-18 activity and on IL-18's affinitieswith varvIL-18BP and hIL-18Rα also demonstrates that the
substitution does not cause the effect by a general, indirect
effect on hIL-18 structure.
Materials and methods
Construction of expression vectors for hIL-18, varvIL-18BP
and hIL-18Rα ectodomain
The coding sequence for hIL-18 with its caspase-1
cleavage site mutated to the Factor Xa site was generated
by recombinant PCR as follows. Two separate PCR reactions
were performed with a hIL-18 cDNA clone (MGC-12320;
ATCC) as the template and the primers sets (5-GGGAATTC-
CATATGGCTGCTGAACCAGTAG-3′ and 5′-GCCAAAG-
TAACGTCCTTCGATGTTTTCATC-3′) or (5′-GATGAAAA-
CATCGAAGGACGTTACTTTGGC-3′ and 5′-CGCGGA-
TCCTAGTCTTCGTTTTGAACAGTG-3′). The sequences in
the primers that change the coding sequence of the caspase-1
cleavage site are underlined and the appended NdeI and the
BamHI sites are shown in bold italics. The two PCR products
were gel-purified and used together as the template in a
recombinant PCR reaction. The product was cloned into the
NdeI and BamHI sites of a vector that was constructed by
removing the coding sequence for the thrombin cleavage site
from pET15b (Novagen). The resulting plasmid, designated as
pYW1, encodes proIL-18 with the Factor Xa cleavage site and
an N-terminal 6-His tag (Fig. 1B). Recombinant PCR reaction
was similarly performed to introduce single amino acid
substitutions into hIL-18 coding sequence in pYW1.
The coding sequence for variola virus IL-18BP (varvIL-
18BP) was constructed by site-directed mutagenesis of
ectromelia virus IL-18BP (ectvIL-18BP) as follows. The
coding sequence for amino acid 71 to 121 of ectvIL-18BP was
amplified by PCR from genomic DNA of ectromelia virus
naval strain (a gift from Dr. Antonio Alcami), with primers 5′-
CTGGGCGATGGCATCAAAGAAGATGAAACCATTCG-
TACCA-3′ and 5′-TTTTGAAACGCCATTTAGCGTAGTGA-
GGAC-3′. The underlined sequence in the primers represents
changes from the wild type sequence to simultaneously intro-
duce N76K, V81I and D116N substitutions. The PCR product
was then further amplified by PCR to extend the coding se-
quence to amino acid 63 to 127, with primers 5′-CGAGTA-
TACCAAGTTTATAGAACATCTGGGCGATGGCATC-3′
and 5′-CTTCAGCCAAATATTCTTTTTTGAAACGCCATTT-
3′. The underlined sequence in the primers denotes changes
from the wild type sequence to introduce the D64Y substi-
tution. The PCR product, which encodes the C-terminal half
of ectvIL-18BP with four amino acids substituted, was cloned
into pCR2.1 vector using a TA cloning system (Invitrogen),
yielding pTS1. Separately, the coding sequence for the N-
terminal half of ectvIL-18BP containing the H38Y and E48K
substitutions was constructed by recombinant PCR with ectro-
melia virus genomic DNA as the template and the primer sets
(5′-ATATAGGATCCATGAGAATCCTA-3′ and 5′-GTTCCA-
CACATCCTGAACAATAAAATTCTCCAG-3′) and (5′-
CAGGATGTGTGGAACATATGCCTAAGTTTAGCTA-3′
Fig. 5. The binding affinity of hIL-18 with hIL-18Rα is reduced by alanine substitution of Leu5, Lys53 or Ser55. (A) Detection of in vitro biotinylated hIL-18Rα
ectodomain. Recombinant hIL-18Rα ectodomain was purified and biotinylated similarly as describe in Fig. 2. The biotinylated species were detected with a
streptavidin–horseradish peroxidase conjugate. (B) Kinetic analyses of hIL-18Rα binding by L5A, E6A, K53A and S55A mutants. The biotinylated hIL-18Rα
ectodomain was captured on a BIAcore SA chip, and its binding with hIL-18 proteins was monitored with a BIAcore 3000 sensor. BIAcore sensorgrams obtained with
different concentrations of the same hIL-18 mutant were globally fitted to a 1:1 binding model and the obtained kinetics constants are shown.
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derlined sequence in the primers denotes changes from the
wild type sequence to introduce the H38Y and E48K substi-
tutions. The BamHI and the AccI sites in the primers are
shown in bold italics. These sites were used to clone the
recombinant PCR product into the corresponding sites of
pTS1 to generate the entire coding sequence for varvIL-18BP.
The mammalian expression vector for varvIL-18BP with a
C-terminal biotinylation site and a 6-His tag was constructed as
previously described for the construction of other IL-18BPs
expression vectors (Xiang and Moss, 2001b). Briefly, thecoding sequence for varvIL-18BP was amplified by PCR using
primers 5′-CTATCAGCTAGCATGAGAATCCTATTTCT-3′
and 5′-TAATGGATCCACCACCTCCACCCTTCAGCCAAA-
TATT-3′. The NheI and BamHI sites in the primers are shown in
bold italics, and they were used to clone the PCR product into
the corresponding sites in pYX45 (Xiang and Moss, 2001b),
resulting in the fusion of the varvIL-18BP coding sequence in
frame with the coding sequence for the biotinylation site and a 6-
His tag that are present in pYX45. Similarly, the coding
sequence for ectvIL-18BP was cloned into pYX45 for making
the mammalian expression vector for ectvIL-18BP.
Fig. 6. S55A substitution enhances IL-18 activity at low hIL-18 concentrations.
1×106 KG-1 cells in 250 μl were stimulated with different amount of hIL-18 at
37 °C. After 24 h, 100 μl of clarified supernatants were assayed for human IFN-
γ with ELISA. The assay was done in duplicate with the standard deviation
shown.
218 X. Meng et al. / Virology 358 (2007) 211–220The mammalian expression vector for hIL-18Rα ectodomain
with a C-terminal biotinylation site and a 6-His tag was
constructed as follows. The coding sequence for hIL-18Rα
ectodomain (amino acid 1–229) was amplified by PCR from
reverse-transcribed cDNA of human KG-1 cells using primers
5′-CTATCAGCTAGCGCCACCATGAATTGTAGAGAAT-
TACCCTTGACCC-3′ and 5′-GAAGATCTACCACCTC-
CACCTCTTGTGAAGACGTG-3′. The NheI and BglII sites
in the primers are shown in bold italics. The PCR product was
digested with NheI and BglII and ligated with pYX45 vector
that was digested with NheI and BamHI.
The fidelity of each construct was confirmed by sequencing
with an ABI 3100 Genetic Analyzer.
Expression and purification of hIL-18 proteins
The expression construct for wild type or mutated hIL-18 was
transformed into E. coli strain BL21(DE3). A 5 ml overnightFig. 7. (A) Leu5, Lys53 and Ser55 of hIL-18 are located at a contiguous surface patch.
spacefill. Three residues (Leu5, Lys53 and Ser55) that contribute to binding with bot
significantly to binding with either varvIL-18BP or IL-18Rα, is shown in gray. The rem
shown in orange. (B) Locations in a hIL-18BP structure model (Kim et al., 2000) of t
18BP residues were identified previously (Xiang andMoss, 2001b) and are conserved
shown in spacefill with their residue numbers.culture from a single colony was inoculated to 500 ml of LB
medium containing 100 μg/ml ampicillin. When the culture
grew to a density of 0.7–0.8 A600, protein expression was
induced by adding 1 mM of isopropylthiogalactoside (IPTG)
and incubated at 25 °C with shaking for 4–5 h. Bacteria were
harvested by centrifugation (5,000×g for 15 min at 4 °C). The
pellet was suspended with 10 ml of B-PER buffer (Pierce) and
further lysed by sonication on ice for 2 min. The soluble protein
was clarified by centrifugation (27,000×g, 15 min, 4 °C) and
bound to a 1 ml Ni-nitrilotriacetic acid resin (Ni-NTA; Qiagen)
overnight in the presence of 10 mM imidazole. The resin was
washed three times with 10 ml of 10 mM imidazole in
phosphate-buffered saline (PBS) and once with Factor Xa buffer
(20 mMTris–HCl pH 8.0, 100 mMNaCl and 2 mMCaCl2). The
proteins bound to the resin were digested with Factor Xa at 4 °C
for 8 h by suspending the resin in 1.5 ml of Factor Xa buffer with
5 μg of Factor Xa (New England Biolabs). The clarified
supernatant from the resin was applied to a sephacryl S-100HR
column controlled by an Amersham ACTA Purifier, and 1 ml
fraction was collected. Purity of the products was determined by
10% SDS-PAGE under reducing conditions followed by
Coomassie blue and silver staining. The protein concentrations
were determined by Bradford protein assay (Biorad).
IL-18BP and IL-18Rα protein purification and in vitro
biotinylation
The varvIL-18BP and IL-18Rαwere expressed in HEK293T
cells, purified from the culture medium and biotinylated
essentially as described previously (Xiang and Moss, 2001b).
Briefly, 293T cells were transfected with the expression plasmid
using Lipofectamine (Invitrogen). After overnight incubation,
the medium was replaced with serum free DMEM (Invitrogen).
After another 3 days of incubation, the medium was harvested,
clarified by centrifugation and incubated with Ni-NTA resin.
The resin was then washed and added with E. coli biotin
holoenzyme synthetase (BirA; Avidity). The resin wasThe hIL-18 residues at or near the known binding site II for IL-1Rα are shown in
h varvIL-18BP and IL-18Rα are shown in red. Glu6, which does not contribute
aining site II residues, which do not contribute to binding with varvIL-18BP, are
hree residues that contribute most significantly to hIL-18 binding. The three hIL-
between human and poxviral IL-18BPs. The side chains of the three residues are
219X. Meng et al. / Virology 358 (2007) 211–220incubated with shaking at 37 °C for 1 to 4 h, washed with
15 mM imidazole in PBS containing 150 mM NaCl. The
recombinant protein was eluted with 2 ml of 300 mM
imidazole in PBS and was used directly for analysis with a
BIAcore 3000 sensor (BIAcore, Piscataway, NJ).
Surface plasmon resonance (SPR)
The SPR analysis was done essentially as described
previously (Xiang and Moss, 2001a, 2001b). Briefly, biotiny-
lated varvIL-18BP or hIL-18Rα was captured onto a BIAcore
SA chip coated with streptavidin. Various concentrations of
hIL-18 were injected at a flow rate of 20 μl/min. The chip
coated with varvIL-18BP was regenerated with a 10-μl injection
of 10 mM glycine (pH 1.5), while the chip coated with hIL-
18Rα was regenerated with a 10-μl injection of 10 mM NaOH.
The sensorgrams were analyzed with BIAEVALUATION
software (BIAcore). The binding data from the injection of at
least four different concentrations of analyte were globally fitted
to a 1:1 binding model. Analyses with the same concentration
series were done twice.
IL-18 bioassay
The IL-18 bioassay was done similarly as previously des-
cribed (Xiang and Moss, 1999). Briefly, KG-1 cells (0.25 ml at
1×106 per ml) in RPMI medium containing 10% FBS were
seeded in wells of a 96-well plate and stimulated with different
concentrations of hIL-18. After stimulation at 37 °C for 24 h,
100 μl of clarified supernatants was assayed for human IFN-γ
by ELISA (BD Biosciences). The IL-18 assay was done in
duplicates.
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